Home
Storia in 2 fonti
Cancer drug licensed by GSK from China posts promising trial results
Mo-Rez, developed by Hansoh Pharma, is a next-generation treatment for ovarian and endometrial cancer
- ·
ft.com
Cancer drug licensed by GSK from China posts promising trial results
Mo-Rez, developed by Hansoh Pharma, is a next-generation treatment for ovarian and endometrial cancer
- ·
theguardian.com
GSK reports promising early results in ovarian and womb cancer drug trial
Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug
- ·
Merck transforms itself through dealmaking as clock ticks on top-selling drug
Acquisitions fuel pharma group’s evolution as it prepares to lose patent protection on cancer drug Keytruda